About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Docs on Twitter


Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Supreme Court Denies Israel Bio-Engineering Project Certiorari Petition | Main | Why We Don't Know What Causes Human Cancer »

June 27, 2007

Novogen and Chattem Reach Settlement

    By Jason Derry --

000095013305004931_w14381logo Novogen Ltd. and Chattem, Inc. have reached a settlement, ending the legal action regarding isoflavone-containing health supplements.  Novogen filed suit against Chattem, alleging that Chattem certain Chattem menopause products infringed two of Novogen's U.S. patents - in particular, U.S. Patent Nos. 6,562,380 and 6,987,098.

200_2 Novogen has previously enforced its patents against several other health supplement providers in the U.S. and Canada.  The details of the settlement have not been made public.  Novagen's press release on the settlement can be found here.

Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.

Posted at 11:57 PM in Patent Litigation |

Comments

The comments to this entry are closed.

September 2023

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Categories

Archives

More...